| Literature DB >> 27330313 |
Jian Zhang1, Xu Liu2, Liang-Hao You1, Rui-Zhi Zhou1.
Abstract
HOTAIR, a well-known long non-coding RNA, is involved in carcinogenesis and progression of multiple cancers. Molecular epidemiological studies suggest that HOTAIR polymorphisms may be associated with cancer susceptibility, but the results remain controversial. To derive a more precise evaluation, we performed a meta-analysis focused on the associations between HOTAIR polymorphisms and cancer risk for the first time. PubMed, Embase, China National Knowledge Infrastructure, and Wanfang databases were searched. Odds ratios (ORs) with 95% confidence interval (CI) were applied to assess the association between HOTAIR rs920778 C>T, rs4759314 A>G, rs7958904 G>C, and rs1899663 G>T polymorphisms and cancer susceptibility. Analyses were conducted to detect heterogeneity, sensitivity, and publication bias in order to measure the robustness of our findings. Overall, 13 related studies involving 7,151 patients and 8,740 control samples were analyzed. Significant associations between the HOTAIR rs920778 polymorphism and cancer risk were observed (T vs C: OR =1.33, 95% CI =1.17-1.53; TT vs TC + CC: OR =1.55, 95% CI =1.21-2.00; TC + TT vs CC: OR =1.33, 95% CI =1.11-1.59; TT vs CC: OR =2.02, 95% CI =1.31-3.10) in the total population, as well as in subgroup analyses. For rs4759314 A>G polymorphism, a similarly increased risk was found in the gastric cancer group. However, significant decreases in cancer risk were observed both in the overall population and colorectal cancer group for rs7958904 G>C polymorphism. In addition, no significant association was detected between rs1899663 G>T polymorphism and cancer susceptibility. In conclusion, our meta-analyses suggest that HOTAIR polymorphisms may be associated with the risk of cancer development.Entities:
Keywords: HOTAIR; cancer susceptibility; polymorphism
Year: 2016 PMID: 27330313 PMCID: PMC4898434 DOI: 10.2147/OTT.S107190
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Flow diagram of the study selection process.
Characteristics of case-control studies on HOTAIR polymorphisms and cancer risk included in the meta-analysis
| Reference | Year | Country/region | Ethnicity | Source of controls | Case | Control | Genotype distribution
| Genotyping methods | Age- and sex-matched | Type of cancer | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | |||||||||||||||
| Pan et al | 2016 | People’s Republic of China | Asian | Population | 500 | 1,000 | 31 | 194 | 275 | 24 | 368 | 608 | RFLP | Matched | Gastric cancer | 0.000 |
| Pan et al | 2016 | People’s Republic of China | Asian | Population | 300 | 600 | 28 | 127 | 145 | 21 | 207 | 372 | RFLP | Matched | Gastric cancer | 0.230 |
| Bayram et al | 2015 | Turkey | Caucasian | Hospital | 104 | 209 | 32 | 52 | 20 | 66 | 105 | 38 | Taqman | Matched | Gastric cancer | 0.738 |
| Bayram et al | 2015 | Turkey | Caucasian | Hospital | 123 | 122 | 40 | 52 | 31 | 41 | 66 | 15 | Taqman | Matched | Breast cancer | 0.140 |
| Yan et al | 2015 | People’s Republic of China | Asian | Population | 502 | 504 | 339 | 151 | 12 | 296 | 190 | 18 | RFLP | Matched | Breast cancer | 0.748 |
| Zhang et al | 2014 | People’s Republic of China | Asian | Population | 1,000 | 1,000 | 83 | 389 | 528 | 41 | 358 | 601 | RFLP | Matched | Esophageal cancer | 0.173 |
| Zhang et al | 2014 | People’s Republic of China | Asian | Hospital | 510 | 550 | 47 | 207 | 256 | 20 | 186 | 344 | RFLP | Matched | Esophageal cancer | 0.401 |
| Zhang et al | 2014 | People’s Republic of China | Asian | Population | 588 | 600 | 51 | 203 | 307 | 17 | 205 | 378 | RFLP | Matched | Esophageal cancer | 0.082 |
| Pan et al | 2016 | People’s Republic of China | Asian | Population | 500 | 1,000 | 1 | 48 | 451 | 3 | 83 | 914 | RFLP | Matched | Gastric cancer | 0.448 |
| Du et al | 2015 | People’s Republic of China | Asian | Hospital | 753 | 1,057 | 3 | 126 | 624 | 6 | 136 | 915 | Taqman | Matched | Gastric cancer | 0.699 |
| Du et al | 2015 | People’s Republic of China | Asian | Hospital | 522 | 589 | 3 | 60 | 459 | 2 | 36 | 549 | Taqman | Matched | Gastric cancer | 0.098 |
| Yan et al | 2015 | People’s Republic of China | Asian | Population | 502 | 504 | 1 | 50 | 451 | 2 | 54 | 448 | RFLP | Matched | Breast cancer | 0.785 |
| Guo et al | 2015 | People’s Republic of China | Asian | Population | 515 | 654 | 1 | 53 | 461 | 1 | 64 | 589 | RFLP | Unmatched | Gastric cancer | 0.587 |
| Xue et al | 2015 | People’s Republic of China | Asian | Hospital | 1,147 | 1,203 | 1 | 135 | 1,011 | 9 | 157 | 1,037 | Taqman | Matched | Colorectal cancer | 0.260 |
| Xue et al | 2015 | People’s Republic of China | Asian | Hospital | 587 | 652 | 4 | 65 | 517 | 2 | 79 | 571 | Taqman | Matched | Colorectal cancer | 0.673 |
| Zhang et al | 2014 | People’s Republic of China | Asian | Population | 1,000 | 1,000 | 2 | 81 | 917 | 1 | 89 | 910 | RFLP | Matched | Esophageal cancer | 0.436 |
| Du et al | 2015 | People’s Republic of China | Asian | Hospital | 753 | 1,057 | 51 | 276 | 412 | 85 | 404 | 568 | Taqman | Matched | Gastric cancer | 0.271 |
| Xue et al | 2015 | People’s Republic of China | Asian | Hospital | 1,147 | 1,203 | 74 | 399 | 672 | 99 | 456 | 646 | Taqman | Matched | Colorectal | 0.147 |
| Xue et al | 2015 | People’s Republic of China | Asian | Hospital | 587 | 652 | 33 | 206 | 347 | 57 | 248 | 346 | Taqman | Matched | Colorectal | 0.192 |
| Pan et al | 2016 | People’s Republic of China | Asian | Population | 500 | 1,000 | 6 | 118 | 376 | 13 | 255 | 732 | RFLP | Matched | Gastric cancer | 0.078 |
| Yan et al | 2015 | People’s Republic of China | Asian | Population | 502 | 504 | 14 | 149 | 339 | 20 | 158 | 326 | RFLP | Matched | Breast cancer | 0.876 |
| Zhang et al | 2014 | People’s Republic of China | Asian | Population | 1,000 | 1,000 | 19 | 256 | 725 | 26 | 250 | 724 | RFLP | Matched | Esophageal cancer | 0.430 |
Note:
HWE in control.
Abbreviations: HWE, Hardy-Weinberg equilibrium; RFLP, restriction fragment length polymorphism.
Figure 2Calculated OR and 95% CIs for the associations between HOTAIR rs920778 polymorphism and cancer risk in overall populations.
Notes: (A) The allele contrast model; (B) the recessive model; (C) the dominant model; (D) the homozygous (co-dominant) model. The area of each square indicates the weight of the study in the meta-analysis. Weights are from random effect analysis.
Abbreviations: OR, odds ratio; CIs, confidence intervals.
Summary of ORs and 95% CI of HOTAIR polymorphisms and cancer risk
| Locus | N | Number of case/control | Allele
| Recessive
| Dominant
| Homozygote
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |||||||||||
| Total | 8 | 3,627/4,585 | 1.33 | 1.17–1.53 | <0.001 | 68.1 | 1.55 | 1.21–2.00 | 0.001 | 59.7 | 1.33 | 1.11–1.59 | 0.002 | 63.6 | 2.01 | 1.31–3.10 | 0.001 | 77.0 |
| Ethnicity | ||||||||||||||||||
| Asian | 6 | 3,400/4,254 | 1.44 | 1.34–1.56 | <0.001 | 2.9 | 1.77 | 1.30–2.41 | <0.001 | 66.0 | 1.44 | 1.30–1.58 | <0.001 | 0 | 2.77 | 2.22–3.44 | <0.001 | 0 |
| Caucasian | 2 | 227/331 | 0.86 | 0.67–1.10 | 0.218 | 0 | 1.06 | 0.74–1.51 | 0.768 | 0 | 0.63 | 0.29–1.40 | 0.257 | 67.4 | 0.68 | 0.41–1.12 | 0.129 | 39.4 |
| Source of controls | ||||||||||||||||||
| Population | 5 | 2,890/3,704 | 1.42 | 1.30–1.54 | <0.001 | 0 | 1.76 | 1.23–2.51 | 0.002 | 70.8 | 1.40 | 1.25–1.56 | <0.001 | 0 | 2.70 | 2.12–3.42 | <0.001 | 0 |
| Hospital | 3 | 737/881 | 1.07 | 0.66–1.75 | 0.778 | 87.9 | 1.27 | 0.94–1.70 | 0.118 | 38.1 | 0.90 | 0.40–2.03 | 0.808 | 87.3 | 1.14 | 0.37–3.55 | 0.825 | 88.8 |
| Method | ||||||||||||||||||
| Taqman | 2 | 227/331 | 0.86 | 0.67–1.10 | 0.218 | 0 | 1.06 | 0.74–1.51 | 0.768 | 0 | 0.63 | 0.29–1.40 | 0.257 | 67.4 | 0.68 | 0.41–1.12 | 0.129 | 39.4 |
| RFLP | 6 | 3,400/4,254 | 1.44 | 1.34–1.56 | <0.001 | 2.9 | 1.77 | 1.30–2.41 | <0.001 | 66.0 | 1.44 | 1.30–1.58 | <0.001 | 0 | 2.77 | 2.22–3.44 | <0.001 | 0 |
| Type of cancer | ||||||||||||||||||
| Gastric cancer | 3 | 904/1,809 | 1.32 | 1.01–1.72 | 0.045 | 73.8 | 1.61 | 0.95–2.72 | 0.078 | 63.5 | 1.36 | 1.02–1.83 | 0.039 | 59.0 | 2.12 | 1.00–4.51 | 0.050 | 78.1 |
| Breast cancer | 2 | 625/626 | 1.03 | 0.57–1.86 | 0.917 | 87.2 | 1.14 | 0.94–1.37 | 0.181 | 0 | 0.79 | 0.22–2.78 | 0.709 | 84.3 | 0.90 | 0.25–3.20 | 0.873 | 82.4 |
| Esophageal cancer | 3 | 2,098/2,150 | 1.46 | 1.32–1.61 | <0.001 | 0.8 | 1.96 | 1.48–2.59 | <0.001 | 0 | 1.44 | 1.27–1.62 | <0.001 | 0 | 2.81 | 2.13–3.71 | <0.001 | 2.2 |
| Controls in HWE | 7 | 3,127/3,585 | 1.33 | 1.14–1.56 | <0.001 | 72.2 | 1.48 | 1.14–1.92 | 0.003 | 57.8 | 1.32 | 1.06–1.65 | 0.012 | 67.6 | 1.90 | 1.16–3.12 | 0.011 | 79.7 |
| Total | 8 | 5,526/6,659 | 1.07 | 0.90–1.28 | 0.461 | 59.9 | 0.68 | 0.36–1.29 | 0.233 | 0 | 1.08 | 0.90–1.30 | 0.401 | 59.1 | 0.75 | 0.40–1.40 | 0.366 | 0 |
| Source of controls | ||||||||||||||||||
| Population | 4 | 2,517/3,158 | 1.00 | 0.84–1.19 | 0.962 | 0 | 0.93 | 0.29–3.00 | 0.898 | 0 | 1.00 | 0.83–1.20 | 0.977 | 0 | 0.93 | 0.29–2.99 | 0.901 | 0 |
| Hospital | 4 | 3,009/3,501 | 1.15 | 0.83–1.61 | 0.403 | 81.1 | 0.59 | 0.28–1.28 | 0.184 | 34.6 | 1.18 | 0.83–1.66 | 0.356 | 80.2 | 0.69 | 0.33–1.45 | 0.325 | 48.4 |
| Method | ||||||||||||||||||
| Taqman | 4 | 3,009/3,501 | 1.15 | 0.83–1.61 | 0.403 | 81.1 | 0.59 | 0.28–1.28 | 0.184 | 34.6 | 1.18 | 0.83–1.66 | 0.356 | 80.2 | 0.69 | 0.33–1.45 | 0.325 | 48.4 |
| PCR-RFLP | 4 | 2,517/3,158 | 1.00 | 0.84–1.19 | 0.962 | 0 | 0.93 | 0.29–3.00 | 0.898 | 0 | 1.00 | 0.83–1.20 | 0.977 | 0 | 0.93 | 0.29–2.99 | 0.901 | 0 |
| Type of cancer | ||||||||||||||||||
| Gastric cancer | 4 | 2,290/3,300 | 1.29 | 1.10–1.51 | 0.002 | 43.5 | 0.69 | 0.27–1.74 | 0.430 | 0 | 1.32 | 1.12–1.56 | 0.001 | 44.0 | 0.97 | 0.39–2.41 | 0.954 | 0 |
| Breast cancer | 1 | 502/504 | 0.90 | 0.61–1.32 | 0.571 | NA | 0.55 | 0.05–6.24 | 0.629 | NA | 0.91 | 0.61–1.35 | 0.625 | NA | 0.50 | 0.05–5.50 | 0.568 | NA |
| Colorectal cancer | 2 | 1,734/1,855 | 0.86 | 0.71–1.04 | 0.123 | 0 | 0.60 | 0.03–10.39 | 0.724 | 77.6 | 0.87 | 0.72–1.06 | 0.177 | 0 | 0.53 | 0.03–10.40 | 0.677 | 79.8 |
| Esophageal cancer | 1 | 1,000/1,000 | 0.93 | 0.69–1.26 | 0.644 | NA | 2.17 | 0.19–24.36 | 0.531 | NA | 0.92 | 0.67–1.25 | 0.578 | NA | 1.99 | 0.18–21.93 | 0.576 | NA |
| Age- and sex-matched | 7 | 5,011/6,005 | 1.07 | 0.88–1.31 | 0.497 | 65.7 | 0.66 | 0.34–1.27 | 0.210 | 0 | 1.09 | 0.88–1.34 | 0.434 | 65.0 | 0.73 | 0.38–1.39 | 0.335 | 7.2 |
| Total | 3 | 2,487/2,912 | 0.85 | 0.78–0.93 | <0.001 | 0 | 0.85 | 0.69–1.06 | 0.143 | 0 | 0.84 | 0.76–0.94 | 0.002 | 0 | 0.72 | 0.58–0.89 | 0.002 | 0 |
| Type of cancer | ||||||||||||||||||
| Gastric cancer | 1 | 753/1,057 | 0.92 | 0.79–1.07 | 0.292 | NA | 0.90 | 0.62–1.31 | 0.570 | NA | 0.92 | 0.76–1.11 | 0.399 | NA | 0.83 | 0.57–1.20 | 0.314 | NA |
| Colorectal cancer | 2 | 1,734/1,855 | 0.82 | 0.74–0.91 | <0.001 | 0 | 0.83 | 0.64–1.08 | 0.163 | 0 | 0.81 | 0.71–0.92 | 0.001 | 0 | 0.67 | 0.51–0.87 | 0.002 | 0 |
| Total | 3 | 2,002/2,504 | 0.93 | 0.83–1.04 | 0.208 | 0 | 0.79 | 0.52–1.20 | 0.265 | 0 | 0.94 | 0.82–1.07 | 0.334 | 0 | 0.74 | 0.49–1.11 | 0.147 | 0 |
Notes:
Numbers of comparisons.
Test for heterogeneity. P-values were obtained from Z-test.
Abbreviations: RFLP, restriction fragment length polymorphism; HWE, Hardy-Weinberg equilibrium; NA, not available; ORs, odds ratios; CI, confidence interval; PCR, polymerase chain reaction.
Figure 3Sensitivity analysis via deletion of each individual study reflects the relative influence of each individual dataset on the pooled ORs in the allele contrast model of HOTAIR rs920778 polymorphism.
Abbreviation: ORs, odds ratios.
Figure 4Funnel plot analysis to detect publication bias for the allele contrast model of HOTAIR rs920778 polymorphism.
Abbreviation: SE, standard error.